Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes.

Our findings indicate that the ubiquitin-proteasome system might not be the main mechanism of mutant dysferlin degradation. However, its inhibition could help to improve muscle inflammation by reducing TSP-1 release.